Mesopancreatic Excision for Pancreatic Duct Adenocarcinoma.

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with high rates of local recurrence and distant metastasis. Recent evidence suggests that mesopancreatic excision (TMpE) may improve R0 resection rates, reduce local recurrence, and enhance overall survival compared to standard pancreatoduodenectomy. However, most existing studies are retrospective with heterogeneous patient populations and surgical techniques. This prospective study aims to evaluate the impact of mesopancreatic excision, a surgical technique involving the meticulous removal of retroperitoneal tissue surrounding

Trial Details

NCT ID
NCT07148830
Phase
NA
Sponsor
Minia University
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Total Mesopancreas Excision (TMpE) (as part of Pancreaticoduodenectomy)
Locations (sample)
  • Minya, Minya Governorate, Egypt|28.09193,30.75813

Key Eligibility Criteria

  • Age ≥18 years.
  • Patients scheduled to undergo pancreaticoduodenectomy with planned mesopancreatic excision.
  • Histologically confirmed PDAC of the pancreatic head (via endoscopic ultrasound-guided biopsy).
  • Resectable disease per National Comprehensive Cancer Network(NCCN) guidelines (no distant metastases, no arterial involvement \>180°, venous involv…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →